Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study-Joint and Skin (BeRLiSS-JS).
Zen M, Gatto M, Depascale R, Regola F, Fredi M, Andreoli L, Franceschini F, Urban ML, Emmi G, Ceccarelli F, Conti F, Bortoluzzi A, Govoni M, Tani C, Mosca M, Ubiali T, Gerosa M, Bozzolo EP, Canti V, Cardinaletti P, Gabrielli A, Tanti G, Gremese E, De Marchi G, De Vita S, Fasano S, Ciccia F, Pazzola G, Salvarani C, Negrini S, Di Matteo A, De Angelis R, Orsolini G, Rossini M, Faggioli P, Laria A, Piga M, Cauli A, Scarpato S, Rossi FW, De Paulis A, Brunetta E, Ceribelli A, Selmi C, Prete M, Racanelli V, Vacca A, Bartoloni E, Gerli R, Zanatta E, Larosa M, Saccon F, Doria A, Iaccarino L. Zen M, et al. Among authors: laria a. J Pers Med. 2023 Apr 20;13(4):691. doi: 10.3390/jpm13040691. J Pers Med. 2023. PMID: 37109077 Free PMC article.
Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting.
Gatto M, Saccon F, Zen M, Regola F, Fredi M, Andreoli L, Tincani A, Urban ML, Emmi G, Ceccarelli F, Conti F, Bortoluzzi A, Govoni M, Tani C, Mosca M, Ubiali T, Gerosa M, Bozzolo E, Canti V, Cardinaletti P, Gabrielli A, Tanti G, Gremese E, De Marchi G, De Vita S, Fasano S, Ciccia F, Pazzola G, Salvarani C, Negrini S, Puppo F, Di Matteo A, De Angelis R, Orsolini G, Rossini M, Faggioli P, Laria A, Piga M, Mathieu A, Scarpato S, Rossi FW, de Paulis A, Brunetta E, Ceribelli A, Selmi C, Prete M, Racanelli V, Vacca A, Bartoloni E, Gerli R, Larosa M, Iaccarino L, Doria A. Gatto M, et al. Among authors: laria a. Arthritis Rheumatol. 2020 Aug;72(8):1314-1324. doi: 10.1002/art.41253. Epub 2020 Jun 12. Arthritis Rheumatol. 2020. PMID: 32275125
Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort.
Gatto M, Saccon F, Andreoli L, Bartoloni E, Benvenuti F, Bortoluzzi A, Bozzolo E, Brunetta E, Canti V, Cardinaletti P, Ceccarelli F, Ciccia F, Conti F, De Marchi G, de Paulis A, De Vita S, Emmi G, Faggioli P, Fasano S, Fredi M, Gabrielli A, Gasparotto M, Gerli R, Gerosa M, Govoni M, Gremese E, Laria A, Larosa M, Mosca M, Orsolini G, Pazzola G, Petricca L, Ramirez GA, Regola F, Rossi FW, Rossini M, Salvarani C, Scarpato S, Tani C, Tincani A, Ubiali T, Urban ML, Zen M, Doria A, Iaccarino L. Gatto M, et al. Among authors: laria a. J Autoimmun. 2021 Nov;124:102729. doi: 10.1016/j.jaut.2021.102729. Epub 2021 Sep 30. J Autoimmun. 2021. PMID: 34600347
Interstitial Lung Disease in Rheumatoid Arthritis: A Practical Review.
Laria A, Lurati AM, Zizzo G, Zaccara E, Mazzocchi D, Re KA, Marrazza M, Faggioli P, Mazzone A. Laria A, et al. Front Med (Lausanne). 2022 May 13;9:837133. doi: 10.3389/fmed.2022.837133. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35646974 Free PMC article. Review.
Immunotherapy of COVID-19: Inside and Beyond IL-6 Signalling.
Zizzo G, Tamburello A, Castelnovo L, Laria A, Mumoli N, Faggioli PM, Stefani I, Mazzone A. Zizzo G, et al. Among authors: laria a. Front Immunol. 2022 Feb 22;13:795315. doi: 10.3389/fimmu.2022.795315. eCollection 2022. Front Immunol. 2022. PMID: 35340805 Free PMC article. Review.
A new digital health tool for the telemonitoring of patients with scleroderma during iloprost administration: a feasibility and acceptability study.
Faggioli P, Zaccara E, Castelnovo L, Bompane D, Tamburello A, Lurati A, Laria A, Gangemi D, Giani M, Gnani D, Di Giorgi M, Iura K, Grandelis F, Piazza R, Piana T, Zizzo G, Mazzone A. Faggioli P, et al. Among authors: laria a. Eur Rev Med Pharmacol Sci. 2023 Jan;27(2):799-804. doi: 10.26355/eurrev_202301_31081. Eur Rev Med Pharmacol Sci. 2023. PMID: 36734722 Free article.
User preference for a portable syringe pump for iloprost infusion.
Laria A, Lurati AM, Re KA, Marrazza MG, Mazzocchi D, Farina A, Scarpellini M. Laria A, et al. Patient Relat Outcome Meas. 2015 May 19;6:139-44. doi: 10.2147/PROM.S81473. eCollection 2015. Patient Relat Outcome Meas. 2015. PMID: 26056502 Free PMC article.
24 results